Research programme: dermatitis therapeutic - Abiogen

Drug Profile

Research programme: dermatitis therapeutic - Abiogen

Alternative Names: KPV; MSH 11-13 monomer

Latest Information Update: 17 Mar 2008

Price : $50

At a glance

  • Originator Abiogen Pharma
  • Class
  • Mechanism of Action Melanocyte stimulating hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Dermatitis

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top